首页> 美国卫生研究院文献>Antibodies >Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies
【2h】

Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies

机译:抗体可变域中的框架和CDR区对Fv和scFv包含双特异性抗体多聚化的相对贡献。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bispecific antibodies represent an emerging class of antibody drugs that are commonly generated by fusion of Fv or scFv antigen binding domains to IgG or Fab scaffolds. Fv- or scFv-mediated multimerisation of bispecific antibodies via promiscuous vH-vL pairing can result in sub-optimal monomer levels during expression, and hence, undesirable therapeutic protein yields. We investigate the contribution of disulphide stabilised Fv and scFv to Fab-Fv and Fab-scFv multimerisation. We show that monomer levels of isolated Fv/scFv cannot always be used to predict monomer levels of Fab-linked Fv/scFv, and that Fab-scFv monomer levels are greater than the equivalent Fab-Fv. Through grafting bispecifics with framework/CDR-‘swapped’ Fv and scFv, we show that monomer levels of disulphide stabilised Fab-Fv and Fab-scFv can be improved by Fv framework ‘swapping’. The Fab-Fv and Fab-scFv can be considered representative of the significant number of bispecific antibody formats containing appended Fv/scFv, as we also used Fv framework ‘swapping’ to increase the monomer level of an IgG-scFv bispecific antibody. This research may, therefore, be useful for maximising the monomeric yield of numerous pharmaceutically-relevant bispecific formats in pre-clinical development.
机译:双特异性抗体代表一类新兴的抗体药物,通常通过Fv或scFv抗原结合域与IgG或Fab支架融合而产生。通过混杂vH-vL配对,Fv或scFv介导的双特异性抗体的多聚化可能导致表达过程中的单体水平欠佳,从而导致治疗性蛋白质收率不理想。我们调查了二硫化物稳定的Fv和scFv对Fab-Fv和Fab-scFv多聚的贡献。我们显示,孤立的Fv / scFv的单体水平不能总是用来预测Fab连接的Fv / scFv的单体水平,并且Fab-scFv单体的水平大于等效的Fab-Fv。通过用框架/ CDR-“交换”的Fv和scFv嫁接双特异性抗体,我们表明,通过Fv框架“交换”可以提高二硫键稳定的Fab-Fv和Fab-scFv的单体水平。可以将Fab-Fv和Fab-scFv视为代表大量附加的Fv / scFv的双特异性抗体形式的代表,因为我们还使用Fv框架“交换”来增加IgG-scFv双特异性抗体的单体水平。因此,该研究对于在临床前开发中最大化许多与药物相关的双特异性形式的单体产率可能是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号